Catalog No.
DHD84001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
IL-12 subunit p40, IL12B, Interleukin-12 subunit beta, IL-12B, CLMF p40, NKSF2, NK cell stimulatory factor chain 2, Cytotoxic lymphocyte maturation factor 40 kDa subunit
Concentration
1.18 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P29460
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CNTO 1275, TT-20, BFI-751, AVT04, CAS: 815610-63-0
Clone ID
Ustekinumab
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis, PMID: 31553833
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease, PMID: 27959607
Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review, PMID: 32562207
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis, PMID: 28423301
Ustekinumab in the management of Crohn's disease: Expert opinion, PMID: 29610019
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease, PMID: 31158271
Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block, PMID: 32027523
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy, PMID: 33086438
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease, PMID: 29909019
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment, PMID: 32441396
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials, PMID: 30097359
Ustekinumab in Pediatric Crohn Disease Patients, PMID: 26854655
[Ustekinumab - Current position], PMID: 30103222
[Ustekinumab], PMID: 31208737
Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease, PMID: 29788272
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs, PMID: 30739254
Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study, PMID: 31219157
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease, PMID: 31279870
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR), PMID: 26151787
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis, PMID: 31816446
Ustekinumab for the treatment of psoriasis: an evidence update, PMID: 30215630
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial, PMID: 26092291
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study, PMID: 32291786
Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center, PMID: 31058718
Ustekinumab treatment for hidradenitis suppurativa, PMID: 31638283
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial, PMID: 28635018
A review of ustekinumab in the treatment of psoriatic arthritis, PMID: 29439608
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy, PMID: 29797519
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis, PMID: 32213052
The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor, PMID: 32249966
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease, PMID: 28365485
Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis, PMID: 31960724
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study, PMID: 33345331
The safety of ustekinumab for the treatment of psoriatic arthritis, PMID: 28441904
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study, PMID: 30249507
Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum, PMID: 26641739
Ustekinumab to treat Crohn's disease, PMID: 29042094
Ustekinumab for the treatment of Crohn's disease, PMID: 27450626
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study, PMID: 27663079
Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature, PMID: 33264569
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy, PMID: 32412134
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY), PMID: 32365251
Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study, PMID: 32901983
Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus, PMID: 31769212
Ustekinumab: A Review in Moderate to Severe Crohn's Disease, PMID: 28528528
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis, PMID: 30945576
Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal, PMID: 29192397
Ustekinumab (Stelara) for Crohn's disease, PMID: 28026835
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study, PMID: 29969700
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis, PMID: 31875504
For research use only. Not for human or drug use.
